Expression of TMED3 is independently associated with colorectal cancer prognosis
- Rong-Fei Wang
- Yong-Gang Hong
- Li-Qiang Hao
- Hai-Tao Yu
Affiliations: Department of Tumor, Anus and Intestine, Jinhua People's Hospital, Jinhua, Zhejiang 321000, P.R. China, Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Oncology, Lanxi People's Hospital, Lanxi, Zhejiang 321100, P.R. China
- Published online on: February 15, 2022 https://doi.org/10.3892/etm.2022.11215
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Colorectal cancer (CRC) is the third most common cancer type and one of the deadliest cancers worldwide. Transmembrane p24 trafficking protein 3 (TMED3) has previously been indicated to suppress CRC metastasis, but its clinical significance has remained undetermined. In the present study, the expression of TMED3 was indicated to be elevated at the mRNA and protein levels in CRC tumor samples relative to that in para‑cancerous healthy tissue samples (P<0.05). Furthermore, Kaplan‑Meier survival analysis revealed a significant negative association between elevated TMED3 protein levels and overall survival of patients with CRC (P<0.001, log‑rank test). Multivariate Cox regression analysis additionally determined that elevated TMED3 expression in primary CRC tumors was an independent predictor of poor prognosis (P<0.05). These results revealed that elevated TMED3 expression in CRC was associated with patient survival outcomes, suggesting that TMED3 may be a potential prognostic biomarker for this cancer type.